X
RXRX icon

Xponance’s Recursion Pharmaceuticals RXRX Stock Holding History

Xponance’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$185K Buy
50,397
+9,151
+22% +$30.5K ﹤0.01% 1625
2026
Q1 		$127K Buy
41,246
+9,900
+32% +$38.3K ﹤0.01% 1543
2025
Q4 		$128K Buy
31,346
+1,326
+4% +$6.57K ﹤0.01% 1444
2025
Q3 		$146K Buy
30,020
+2,221
+8% +$11.7K ﹤0.01% 1398
2025
Q2 		$141K Buy
27,799
+7,655
+38% +$37.6K ﹤0.01% 1373
2025
Q1 		$107K Buy
20,144
+981
+5% +$7.15K ﹤0.01% 1339
2024
Q4 		$130K Buy
19,163
+3,480
+22% +$23.4K ﹤0.01% 1337
2024
Q3 		$103K Buy
15,683
+2,551
+19% +$18.3K ﹤0.01% 1318
2024
Q2 		$98.5K Buy
+13,132
New +$115K ﹤0.01% 1240

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Xponance's RXRX Position: Q2 2026 in Review

Xponance increased its Recursion Pharmaceuticals (RXRX) stake by 22% in Q2 2026, buying an estimated $30.5K and bringing the position to 50,397 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #1625.

Xponance first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Xponance held 50,397 shares of Recursion Pharmaceuticals worth $185K as of Q2 2026.
  • Xponance bought 9,151 Recursion Pharmaceuticals shares in Q2 2026, an estimated $30.5K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1625 holding.
  • Xponance first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.